Abeona Therapeutics Inc. (ABEO) is a Healthcare stock trading at $6.10 (as of 2026-08-21), with a market capitalization of $347.67M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.
Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company developing gene and cell therapies for rare genetic diseases. Its programs include EB-101 (autologous, gene-corrected cell therapy) and multiple AAV-based therapies (ABO-102, ABO-201, ABO-401, and ABO-50X) in areas such as recessive dystrophic epidermolysis bullosa, Sanfilippo syndrome type A, CLN3 disease, cystic fibrosis, and genetic eye disorders.
Abeona Therapeutics develops gene and cell therapies for life-threatening rare genetic diseases, aiming to make money by selling approved treatments and licensing therapies.
The profit model depends on converting clinical-stage therapies into approved products, with sustainable profit requiring patient uptake to cover development and operating costs.
Business quality (Unprofitable): Unprofitable: gross margin 63% has not covered operating costs, reflected in an operating margin of -120%.
| Price | $6.10 |
| Market Cap | $347.67M |
| Price / Book | 2.71 |
| Price / Sales | 14.36 |
| FCF Yield | -23.4% |
| Revenue (TTM) | $5.82M |
| Net Margin | 1223.1% |
| Revenue Growth (YoY) | 2745.0% |
| EPS Growth (YoY) | -116.9% |
| FCF Growth (YoY) | -17.1% |
| Altman Z-Score | -1.63 (distress) |
| Sector P/E (Healthcare) | 21.7 |
| Industry P/E (Pharmaceutical Products) | 17.2 |
| Top Institutional Holder | Nantahala Capital Management, LLC ($22.46M) |
| Institutional Holders Tracked | 10 |
| Sector | Healthcare |
| Industry | Pharmaceutical Products |
| CEO | Vishwas Seshadri |
| Employees | 136 |
| Country | US |
| IPO Date | 1996-04-01 |
Data as of 2026-08-21.
Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.